Dr Helen Pearson

Dr Helen Pearson

COFUND Fellow

School of Biosciences

Email:
pearsonh2@cardiff.ac.uk
Location:
Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ

My lab is investigating the molecular mechanisms that underpin prostate cancer tumourigenesis, progression and resistance to current treatment approaches. This knowledge is applied to the preclinical development of novel, efficacious therapeutic approaches to treat prostate cancer.

Roles

2016 - present: Member of the School of Biosciences Research Ethics Committee (SREC)
2016 - present: Member of the Multidisciplinary Research Group (MDRG) for prostate cancer

Education and qualifications

2008: PhD (Cardiff University, Wales, UK)
2004: BSc (Biochemistry, University of East Anglia, UK + exchange year at Colorado University, Boulder, USA)

Honours and awards

2016 – 2020: Marie Slodowska Curie Actions/Horizon2020/Ser Cymru II Fellowship
2013 – 2014: Richard Pratt Foundation Prostate Cancer Research Fellowship/Victorian Cancer Agency

Professional memberships

2015  The Australian Society for Stem Cell Research (ASSCR)
2014  Australian and New Zealand Urogenital and Prostate (ANZUP) clinical trials group
2010  Australian and Canadian Prostate Cancer Research Alliance (AC-PCRA)
2005  European Association for Cancer Research (EACR)
2005  British Association for Cancer Research (BACR)
2004  Royal Society of Biology (RSB)

Academic positions

2016 – present: Research Fellow, European Cancer Stem Cell Research Centre, Cardiff University, Wales, UK
2012 – 2016:     Senior Research Officer, Peter MacCallum Cancer Centre, Melbourne, Australia
2012 – 2016:     Honorary Fellow, University of Melbourne, The Sir Peter MacCallum Department of Oncology, Melbourne, Australia
2008 – 2012:     Junior Research Officer, Peter MacCallum Cancer Centre, Melbourne,  Australia

Focus

My research into prostate cancer integrates basic cancer biology, biomarker discovery and the preclinical assessment of novel therapeutic approaches with the ultimate goal improve upon the current standard of patient care. The research undertaken employs novel model systems to investigate genetic drivers of prostate cancer initiation and progression, and the preclinical development of innovative therapeutic strategies for prostate cancer.

My research is focused on prostate cancer and has two major themes: Oncogenic signalling and therapeutic resistance. My research group is closely linked to clinicians to facilitate translational research.

Current projects and/or themes within the lab

These include:

  • Establishing how loss of cellular polarity contributes to prostate cancer
  • Delineating molecular mechanisms of resistance to androgen-deprivation therapy
  • Enhancing the therapeutic efficacy of PARP inhibition for the treatment of prostate cancer
  • Ex-vivo models of prostate cancer
  • Prostate cancer stem cells